DAWN vs AURA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
DAWN Captures Institutional Edge (2โ1 Pillars ยท 6โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Day One Biopharmaceuticals, Inc. Common Stock (DAWN) driven by superior Momentum & Technical, Options & Structure while AURA counters with relative strength in Growth & Margin. Fundamentally, DAWN trades at N/M Forward P/E with -51.1% operating margin (+83.9% YoY revenue) versus AURA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, DAWN sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against AURA sits in CONSOLIDATION (22nd %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | DAWN | AURA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.2B | $728.6M | Larger Scale | DAWN |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +83.9% | +0.0% | Higher Growth | DAWN |
| Operating Margin (TTM) Profitability | -51.1% | 0.0% | Higher Margin | AURA |
| Net Profit Margin Profitability | -67.8% | 0.0% | Higher Margin | AURA |
| Return on Equity (ROE) Capital Efficiency | -22.7% | -61.7% | Higher ROE | DAWN |
| 52-Week Range Position Momentum | 100% ($6โ$22) | 52% ($5โ$10) | Stronger Trend | DAWN |
| Beta / 30D Volatility Risk Regime | 0.03ฮฒ ยท 2% Vol | 0.92ฮฒ ยท 75% Vol | Lower Realized Risk | DAWN |
| Unified Institutional Score Composite Signal | 58.3 / 100 (HOLD) | 28.8 / 100 (SELL) | Higher Composite | DAWN |